Literature DB >> 8114067

Growth inhibition of Clostridium difficile by intestinal flora of infant faeces in continuous flow culture.

T Yamamoto-Osaki1, S Kamiya, S Sawamura, M Kai, A Ozawa.   

Abstract

Growth of Clostridium difficile was inhibited more strongly in continuous flow (CF) culture with C. difficile-negative faeces of infants than with C. difficile-positive faeces. Culture of faecal flora of infants yielded a greater variety of bacterial species in C. difficile-negative than in C. difficile-positive faeces. In the mixed CF culture of C. difficile with Enterococcus avium, Bacteroides distasonis, Eubacterium lentum, C. ramosum, C. perfringens and either Escherichia coli or Klebsiella pneumoniae isolated from C. difficile-negative faeces, inhibition of growth of C. difficile was demonstrated when the pH of the culture medium was decreased. Amino-acid analysis of CF cultures showed considerable utilisation of aspartic acid, serine, threonine, arginine and asparagine. A marked increase in concentrations of citrulline and ornithine was found in the culture that inhibited growth of C. difficile. The addition of citrulline and ornithine into a Gifu anaerobic medium (GAM) broth produced no inhibition of growth of C. difficile. The addition of the mixture of the depleted amino acids (aspartic acid, serine, threonine, arginine and asparagine) to the culture filtrate or adjustment of the pH of the culture filtrate induced considerable growth of C. difficile. These results suggest that the inhibition of growth of C. difficile may be due to consumption of amino acids by intestinal flora, and not to the presence of inhibitors produced by the intestinal flora.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8114067     DOI: 10.1099/00222615-40-3-179

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  13 in total

1.  Toxins, butyric acid, and other short-chain fatty acids are coordinately expressed and down-regulated by cysteine in Clostridium difficile.

Authors:  S Karlsson; A Lindberg; E Norin; L G Burman; T Akerlund
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 2.  Diversity, stability and resilience of the human gut microbiota.

Authors:  Catherine A Lozupone; Jesse I Stombaugh; Jeffrey I Gordon; Janet K Jansson; Rob Knight
Journal:  Nature       Date:  2012-09-13       Impact factor: 49.962

3.  Changes in the colon microbiota and intestinal cytokine gene expression following minimal intestinal surgery.

Authors:  Susan Lapthorne; Julie E Bines; Fiona Fouhy; Nicole L Dellios; Guineva Wilson; Sarah L Thomas; Michelle Scurr; Catherine Stanton; Paul D Cotter; Prue M Pereira-Fantini
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

Review 4.  Models for the study of Clostridium difficile infection.

Authors:  Emma L Best; Jane Freeman; Mark H Wilcox
Journal:  Gut Microbes       Date:  2012-03-01

5.  Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions.

Authors:  V K Viswanathan; M J Mallozzi; Gayatri Vedantam
Journal:  Gut Microbes       Date:  2010-06-16

6.  Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.

Authors:  T Louie; M Miller; C Donskey; K Mullane; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

7.  Longitudinal Investigation of Carriage Rates, Counts, and Genotypes of Toxigenic Clostridium difficile in Early Infancy.

Authors:  Hiroyuki Kubota; Hiroshi Makino; Agata Gawad; Akira Kushiro; Eiji Ishikawa; Takafumi Sakai; Takuya Akiyama; Kazunori Matsuda; Rocio Martin; Jan Knol; Kenji Oishi
Journal:  Appl Environ Microbiol       Date:  2016-09-16       Impact factor: 4.792

8.  Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility.

Authors:  Charlie T Seto; Patricio Jeraldo; Robert Orenstein; Nicholas Chia; John K DiBaise
Journal:  Microbiome       Date:  2014-11-25       Impact factor: 14.650

9.  Rebamipide protects small intestinal mucosal injuries caused by indomethacin by modulating intestinal microbiota and the gene expression in intestinal mucosa in a rat model.

Authors:  Satoshi Kurata; Takako Nakashima; Takako Osaki; Naoya Uematsu; Masafumi Shibamori; Kazushi Sakurai; Shigeru Kamiya
Journal:  J Clin Biochem Nutr       Date:  2014-10-04       Impact factor: 3.114

10.  Molecular Characterization of Clostridium difficile Isolates from Human Subjects and the Environment.

Authors:  Tian-tian Tian; Jian-hong Zhao; Jing Yang; Cui-xin Qiang; Zhi-rong Li; Jing Chen; Kai-yue Xu; Qing-qing Ciu; Ru-xin Li
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.